|
Activity Number:
|
374
- Bayesian Clinical Trial Designs with Heterogeneous Patient Subgroups
|
|
Type:
|
Topic Contributed
|
|
Date/Time:
|
Wednesday, August 10, 2022 : 8:30 AM to 10:20 AM
|
|
Sponsor:
|
Biopharmaceutical Section
|
|
Abstract #322229
|
|
|
Title:
|
BAGS: A Bayesian Adaptive Group Sequential Trial Design with Subgroup-Specific Survival Comparisons
|
|
Author(s):
|
Ruitao Lin* and Peter Thall and Ying Yuan
|
|
Companies:
|
MD Anderson and The University of Texas MD Anderson Cancer Center and the University of Texas MD Anderson Cancer Center
|
|
Keywords:
|
Bayesian design;
Group sequential;
Response heterogeneity;
Survival comparison
|
|
Abstract:
|
A Bayesian group sequential design is proposed that performs survival comparisons within patient subgroups in randomized trials where treatment–subgroup interactions may be present. A latent subgroup membership variable is assumed to allow the design to adaptively combine homogeneous subgroups, or split heterogeneous subgroups, to improve the procedure’s within-subgroup power. If a baseline covariate related to survival is available, the design may incorporate this information to improve subgroup identification while basing the comparative test on the average hazard ratio. General guidelines are provided for calibrating prior hyperparameters and design parameters to control the overall Type I error rate and optimize performance. Simulations show that the design is robust under a wide variety of different scenarios. When two or more subgroups are truly homogeneous but differ from the other subgroups, the proposed method is substantially more powerful than tests that either ignore subgroups or conduct a separate test within each subgroup.
|
Authors who are presenting talks have a * after their name.
